This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Wisconsin, Madison Identifier:
First received: August 10, 2001
Last updated: October 10, 2016
Last verified: October 2016

RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery.

PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.

Condition Intervention Phase
Prostate Cancer Dietary Supplement: doxercalciferol Procedure: conventional surgery Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Intermediate endpoint biomarker modulation [ Time Frame: 18 months ]
  • Toxicity [ Time Frame: 30 months ]

Estimated Enrollment: 60
Study Start Date: August 2001
Study Completion Date: August 2008
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Observation, then prostatectomy
Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
Procedure: conventional surgery
Procedure: Prostatectomy for prostate cancer
Other Name: Prostatectomy - no dietary supplement
Active Comparator: Doxercalciferol once daily for 28 days
Dietary supplement once daily to treat prostate cancer for 28 days
Dietary Supplement: doxercalciferol
Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
Other Name: Localized adenocarcinoma of the prostate

Detailed Description:


  • Determine whether doxercalciferol modulates intermediate endpoint biomarkers in the development of prostate cancer in patients with localized prostate cancer.
  • Assess the toxicity of this drug in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to one of 2 arms.

  • Arm I: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
  • Arm II: Patients undergo observation for 28 days. Patients then undergo prostatectomy.

PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study within 18 months.


Ages Eligible for Study:   21 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed localized adenocarcinoma of the prostate
  • Candidate for prostatectomy



  • 21 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • WBC at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.4 mg/dL
  • AST no greater than 3 times normal


  • Creatinine no greater than 2.0 mg/dL
  • Calcium no greater than 10.2 mg/dL
  • No idiopathic urinary calcium stone disease


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • No prior hormonal therapy for prostate cancer
  • No concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride, diethylstilbestrol, or progestins


  • No prior brachytherapy or external beam radiotherapy for prostate cancer


  • See Disease Characteristics


  • At least 7 days since prior vitamin D therapy or calcium supplements
  • No other concurrent vitamin D analogues or calcium supplements
  • No concurrent magnesium-containing antacids
  • No concurrent thiazide-containing diuretics
  • No concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00022412

United States, Iowa
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States, 52242-1002
United States, New York
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, Wisconsin
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, United States, 53705
Meriter Hospital
Madison, Wisconsin, United States, 53715
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792-6164
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States, 53226-3596
Sponsors and Collaborators
University of Wisconsin, Madison
National Cancer Institute (NCI)
Study Chair: George Wilding, MD University of Wisconsin, Madison
  More Information

Responsible Party: University of Wisconsin, Madison Identifier: NCT00022412     History of Changes
Other Study ID Numbers: 2000-595
P30CA014520 ( US NIH Grant/Contract Award Number )
CDR0000068813 ( Other Identifier )
CO99802 ( Other Identifier: University of Wisconsin Carbone Cancer Center )
Study First Received: August 10, 2001
Last Updated: October 10, 2016

Keywords provided by University of Wisconsin, Madison:
adenocarcinoma of the prostate
stage I prostate cancer
stage II prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
1 alpha-hydroxyergocalciferol
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on June 22, 2017